INDAPTUS THERAPEUTICS INC (INDP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.22+5.17%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · INDP
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name has erratic recent earnings surprises and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
INDP — debt issuance
Dated 2026-09-01
Entry into a Material Definitive Agreement. On August 28, 2026, Indaptus Therapeutics, Inc. (the “ Company ”) entered into an Amended and Restated At the Market Offering Agreement (the “ Sales Agreement ”) with H.C. Wainwright & Co., LLC (“ Wainwright ”), which amends and restates in its entirety, and supersedes and replaces, the At The Market Offering Agreement, dated June 1, 2022, between the Company and Wainwright (the “ Original Agreement ”). The Sales Agreement provides for the sale and…
Why it matters: How the company uses funds from the recent stock sale will impact future growth.
Supportive ifManagement shares a clear plan for using the $12 million from the private placement.
Worry ifNo clear plan is shared regarding the use of funds from the private placement.
Why it matters: M&A activity may change the company's finances and growth chances.
Supportive ifA big acquisition or partnership is announced that boosts growth.
Worry ifNo M&A activity or announcements made in the next quarter.
Why it matters: Changes in leadership can impact the company. They also affect how investors feel. Stability matters.
Worry ifNo more executive changes for at least three months after the COO left.
Less concerning ifAnother senior executive will leave the company in the next three months.
Why it matters: Changes in leaders can affect how a company runs. Investors want to see the impact.
Worry ifA new executive is appointed who has a strong track record in biotech.
Less concerning ifOngoing changes in leaders without a clear plan or stable team.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$504 on $10,000 · ±5.0% | How much price usually moves either way. |
| Bad day | $1,435 loss on $10,000 · 14.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,029 loss on $10,000 · 80.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Stable R&D costs could mean a move towards new plans.
Supportive ifR&D expenses remain below $0.5 million for the next two quarters.
Worry ifR&D costs rise above $0.5 million, which may show possible problems.
Why it matters: Changes in R&D spending signal the company's commitment to future projects and growth.
Watch forR&D expenses stay the same or go up. This shows renewed investment in clinical programs.
Also watch forR&D expenses keep going down. This suggests a lack of future development plans.
Why it matters: The recent $12 million private placement boosts the company's cash. This is important for operations.
Supportive ifCash and cash equivalents are over $11.6 million in the next quarterly report.
Worry ifCash and cash equivalents drop below $7.6 million in the next quarterly report.
Why it matters: The company needs strong cash flow to support its work and goals.
Supportive ifThe company gets more money through a new funding round or partnership.
Worry ifThe company reports a decrease in cash reserves below $7.6 million.
Why it matters: A bigger loss would show worse financial health and more problems.
Worry ifQ2 net loss reported at more than $3 million.
Less concerning ifNet loss of $3 million or less shows better cost control.
Why it matters: Stable leadership is important for plans and investor trust.
Worry ifNo new senior executives leave in the next quarter.
Less concerning ifMore senior executives leave or get replaced. This shows ongoing problems.
Why it matters: The Decoy platform review is important for Indaptus's future plans.
Watch forManagement shares good news from the Decoy platform review.
Also watch forManagement decides to stop the Decoy platform with no further work.
Why it matters: Cutting operating costs can help financial health and boost investor trust.
Supportive ifIndaptus reports more cuts in research and admin costs in future quarters.
Worry ifOperating costs go up or do not drop as expected.